What is Wedbush's Forecast for DAWN Q1 Earnings?

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) - Research analysts at Wedbush cut their Q1 2025 EPS estimates for shares of Day One Biopharmaceuticals in a note issued to investors on Monday, April 21st. Wedbush analyst R. Driscoll now anticipates that the company will earn ($0.45) per share for the quarter, down from their previous forecast of ($0.43). Wedbush has a "Outperform" rating and a $32.00 price objective on the stock. The consensus estimate for Day One Biopharmaceuticals' current full-year earnings is ($0.72) per share. Wedbush also issued estimates for Day One Biopharmaceuticals' Q2 2025 earnings at ($0.44) EPS, Q3 2025 earnings at ($0.43) EPS, Q4 2025 earnings at ($0.41) EPS, FY2025 earnings at ($1.73) EPS, FY2026 earnings at ($1.77) EPS, FY2027 earnings at ($1.20) EPS, FY2028 earnings at ($0.09) EPS and FY2029 earnings at $0.86 EPS.

Several other research analysts have also issued reports on the stock. The Goldman Sachs Group decreased their price target on shares of Day One Biopharmaceuticals from $39.00 to $27.00 and set a "buy" rating for the company in a research note on Tuesday, March 25th. Needham & Company LLC reiterated a "buy" rating and set a $32.00 target price on shares of Day One Biopharmaceuticals in a report on Wednesday, February 26th. Bank of America dropped their price target on Day One Biopharmaceuticals from $28.00 to $25.00 and set a "buy" rating on the stock in a research report on Tuesday, January 7th. JPMorgan Chase & Co. reduced their price objective on Day One Biopharmaceuticals from $39.00 to $34.00 and set an "overweight" rating for the company in a research report on Wednesday, March 5th. Finally, HC Wainwright reissued a "buy" rating and issued a $36.00 target price on shares of Day One Biopharmaceuticals in a report on Thursday, April 3rd. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and a consensus price target of $32.29.

Day One Biopharmaceuticals Stock Down 1.9 %

Shares of NASDAQ:DAWN traded down $0.15 during trading on Wednesday, hitting $7.59. The stock had a trading volume of 358,328 shares, compared to its average volume of 1,060,387. The company has a market capitalization of $769.28 million, a PE ratio of -7.38 and a beta of -1.24. The firm's fifty day moving average is $8.36 and its 200 day moving average is $11.57. Day One Biopharmaceuticals has a 12 month low of $6.41 and a 12 month high of $18.07.

Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) last issued its quarterly earnings data on Tuesday, February 25th. The company reported ($0.69) earnings per share for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.34). The firm had revenue of $29.21 million during the quarter, compared to analysts' expectations of $27.11 million.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. GF Fund Management CO. LTD. purchased a new position in shares of Day One Biopharmaceuticals during the 4th quarter worth about $27,000. R Squared Ltd purchased a new position in shares of Day One Biopharmaceuticals during the fourth quarter valued at approximately $31,000. Pallas Capital Advisors LLC bought a new position in shares of Day One Biopharmaceuticals during the first quarter valued at approximately $87,000. Wealth Enhancement Advisory Services LLC purchased a new stake in shares of Day One Biopharmaceuticals in the first quarter worth approximately $88,000. Finally, Exchange Traded Concepts LLC lifted its stake in shares of Day One Biopharmaceuticals by 19.6% during the 1st quarter. Exchange Traded Concepts LLC now owns 14,693 shares of the company's stock worth $117,000 after acquiring an additional 2,407 shares during the last quarter. 87.95% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Day One Biopharmaceuticals

In related news, General Counsel Adam Dubow sold 4,646 shares of Day One Biopharmaceuticals stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $11.96, for a total value of $55,566.16. Following the completion of the transaction, the general counsel now owns 39,602 shares in the company, valued at approximately $473,639.92. This trade represents a 10.50 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Jeremy Bender sold 12,048 shares of the company's stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $11.96, for a total value of $144,094.08. Following the sale, the chief executive officer now owns 128,015 shares in the company, valued at approximately $1,531,059.40. This trade represents a 8.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 21,064 shares of company stock worth $251,925 in the last quarter. 6.20% of the stock is owned by corporate insiders.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.